Sign In
Buy CELC
$88.95
-2.47 (-2.70%)
At Close: Jun 03, 2026
Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript
07:42pm, Thursday, 14'th Nov 2024
Celcuity Inc. (NASDAQ:CELC ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Apoorva Chaloori - ICR Westwicke, Investor Relations Brian Sullivan - Co-Founder & Chief
Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update
04:01pm, Thursday, 14'th Nov 2024
MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial r
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
07:05am, Tuesday, 12'th Nov 2024
MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
07:05am, Thursday, 07'th Nov 2024
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wil
Morgan Stanley's Strategic Reduction in Celcuity Inc Holdings
08:11pm, Monday, 07'th Oct 2024
On September 30, 2024, Morgan Stanley executed a significant transaction involving the sale of 1,443,913 shares of Celcuity Inc (NASDAQ: CELC), a clinical-stage biotechnology company. This move reduce
Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect?
10:56am, Tuesday, 10'th Sep 2024
The consensus price target hints at an 87.6% upside potential for Celcuity (CELC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat
Celcuity (CELC) Upgraded to Buy: Here's Why
01:00pm, Tuesday, 20'th Aug 2024
Celcuity (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript
03:50pm, Friday, 16'th Aug 2024
Celcuity Inc. (NASDAQ:CELC ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 AM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief
Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update
04:01pm, Wednesday, 14'th Aug 2024
MINNEAPOLIS, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial r
Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call
07:05am, Wednesday, 07'th Aug 2024
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wil
Celcuity: Flying A Phase 3 Trial Right Under Your Nose
12:05am, Friday, 05'th Jul 2024
Celcuity Inc. is a cancer-focused biotech company with one pipeline candidate, gedatolisib, showing promise in breast and prostate cancer. Gedatolisib is a differentiated PI3K inhibitor with a favorab
Celcuity To Participate in Jefferies Global Healthcare Conference
04:01pm, Monday, 03'rd Jun 2024
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its partici
Celcuity Announces Pricing of Underwritten Common Stock Offering
07:36am, Thursday, 30'th May 2024
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it plan
Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript
07:43pm, Wednesday, 15'th May 2024
Celcuity Inc. (NASDAQ:CELC ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief Fi
